Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on July 16, 2026, for Damora Therapeutics, Inc. (DMRA), a Cayman Islands exempted company. The filing primarily documents the consummation of the Company's redomestication from the State of Delaware to the Cayman Islands and the entry into new indemnification agreements with directors and executive officers.
Key Financial Metrics
This filing is a current report regarding corporate governance and structural changes; it does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing explicitly states that the redomestication did not have any material accounting implications.
Material Changes Versus Prior Period
- Redomestication: Effective July 16, 2026, the Company converted from a Delaware corporation to a Cayman Islands exempted company. Internal affairs are now governed by Cayman Islands law rather than Delaware law.
- Share Conversion: Each outstanding share of common stock automatically converted into one ordinary share of the Cayman Company. Preferred stock and equity awards (options/RSUs) converted on a one-to-one basis with unchanged terms.
- Trading Symbol and CUSIP: While the Nasdaq trading symbol remains "DMRA," the Company's ordinary shares began trading under a new CUSIP number (G2646Y104) on July 20, 2026.
- Indemnification: New indemnification agreements were executed, replacing and superseding all previous agreements with directors and officers.
- Continuity: The Company's business, management, assets, liabilities, and material contracts remained unchanged. The Company continues to be treated as a U.S. corporation for federal tax purposes.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future business performance. The primary risks and contingencies noted relate to the legal transition:
- Legal Jurisdiction: Shareholder rights and internal governance are now subject to Cayman Islands law, which may differ from Delaware law.
- Shareholder Rights: Certain rights of security holders were modified as a result of the redomestication, detailed in the referenced Proxy Statement.
Investor Verification Checklist
- Verify the new CUSIP number (G2646Y104) for trading purposes effective July 20, 2026.
- Review the Cayman Islands Memorandum and Articles of Association (Exhibit 3.1) to understand changes in shareholder rights and governance.
- Confirm that existing equity awards (options and RSUs) have automatically converted to the new Cayman Company structure without change in terms.
- Check the new Indemnification Agreements (Exhibit 10.1) for updated terms regarding director and officer liability protection.